

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001. Amended 01/01/11

<b>Name of Entity:</b>	Chimeric Therapeutics Limited (ASX: CHM)
<b>ABN:</b>	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director:</b>	Jennifer Chow
<b>Date of Last Notice:</b>	14 December 2021

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Direct and Indirect														
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Held via Employee Share Trust														
Date of change	18 November 2022														
No. of securities held prior to change	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>1,702,914</td><td>10,291,495</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>1,702,914</td><td>10,291,495</td></tr></table>				Shares	Options	Direct	1,702,914	10,291,495	Indirect	-	-	Total	1,702,914	10,291,495
	Shares	Options													
Direct	1,702,914	10,291,495													
Indirect	-	-													
Total	1,702,914	10,291,495													
Class	a) Fully Paid Ordinary Shares b) Unlisted Options														
Number acquired	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td></td><td>b) 17,222,368</td></tr><tr><td>Indirect</td><td>a) 4,338,990</td><td>-</td></tr><tr><td>Total</td><td>4,338,990</td><td>17,222,368</td></tr></table>				Shares	Options	Direct		b) 17,222,368	Indirect	a) 4,338,990	-	Total	4,338,990	17,222,368
	Shares	Options													
Direct		b) 17,222,368													
Indirect	a) 4,338,990	-													
Total	4,338,990	17,222,368													
Number disposed	<table><tr><td></td><td>Shares</td><td>Options</td></tr><tr><td>Direct</td><td>-</td><td>-</td></tr><tr><td>Indirect</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td></tr></table>				Shares	Options	Direct	-	-	Indirect	-	-	Total	-	-
	Shares	Options													
Direct	-	-													
Indirect	-	-													
Total	-	-													

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	a) \$0.092 per share b) Non-cash, see ‘nature of change’ below.														
<b>No. of securities held after change</b>	<table><tr><td></td><td><b>Shares</b></td><td><b>Options</b></td></tr><tr><td>Direct</td><td>1,702,914</td><td>27,514,133</td></tr><tr><td>Indirect</td><td>4,338,990</td><td>-</td></tr><tr><td><b>Total</b></td><td><b>6,041,904</b></td><td><b>27,513,863</b></td></tr></table>				<b>Shares</b>	<b>Options</b>	Direct	1,702,914	27,514,133	Indirect	4,338,990	-	<b>Total</b>	<b>6,041,904</b>	<b>27,513,863</b>
	<b>Shares</b>	<b>Options</b>													
Direct	1,702,914	27,514,133													
Indirect	4,338,990	-													
<b>Total</b>	<b>6,041,904</b>	<b>27,513,863</b>													
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	a) and b) Issue of shares and options as approved by Chimeric Therapeutics Limited shareholders at the Annual General Meeting held on 15 November 2022.														

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

### Part 3 – Closed period

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A



The CFO Solution

+ See chapter 19 for defined terms.